Therefore, in addition to the analysis of CD26 concentration as a predictor of severe outcomes of COVID-19, we suggest the assessment of microvascular function and in vitro functional tests using patients’ sera to predict late vascular complication and proinflammatory endothelial phenotype. The gene discussed is DPP4; the disease is COVID-19.